Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGBC016: Bemcentinib with pembrolizumab/carboplatin/pemetrexed in untreated advanced or metastatic non-squamous NSCLC
2024-511007-41-00Phase 2Completed
- Sponsor
- BerGenBio ASA
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of bemcentinib in Non-small cell lung cancer (NS-NSCLC), sponsored by BerGenBio ASA. Primary endpoints: Incidence of dose limiting toxicities (DLTs) during a 21-day assessment period in treatment cycle 1 (Phase 1b) and Objective response rate (ORR) at 6 and 12 months (Phase 2a). Started Aug 2024; status: completed.
02
Drugs
bemcentinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2024-511007-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511007-41-00.